Bone health in hypogonadal men

Current Opinion in Urology

Volumn 24, Issue 6, 2014, Pages 608-613

  Irwig, Michael S ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Estradiol; Hypogonadism; Osteocalcin; Osteoporosis; Testosterone

Indexed keywords

OPIATE; OSTEOCALCIN; SEX HORMONE; TESTOSTERONE; VITAMIN D; ANDROGEN; NARCOTIC ANALGESIC AGENT;

ANDROGEN THERAPY; ARTICLE; BONE; BONE DENSITY; FRACTURE; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THALASSEMIA; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; ADVERSE EFFECTS; BLOOD TRANSFUSION; COMPLICATION; HORMONE SUBSTITUTION; METABOLISM; OSTEOPOROSIS;

ANALGESICS, OPIOID; ANDROGENS; BLOOD TRANSFUSION; BONE DENSITY; HIV INFECTIONS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; OSTEOCALCIN; OSTEOPOROSIS; TESTOSTERONE; THALASSEMIA; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84927919421     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000104     Document Type: Article

References (23)

1. Drake MT, Murad MH, Mauck KF, et al. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97:1861-1870.
2. Tajar A, Huhtaniemi IT, O'Neill TW, et al., EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012; 97:1508-1516.
3. Watts NB, Adler RA, Bilezikian JP, et al., Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:1802-1822.
4. Hannemann A, Breer S, Wallaschofski H, et al. Osteocalcin is associated with testosterone in the general population and selected patients with bone disorders. Andrology 2013; 1:469-474.
5. Samavat J, Facchiano E, Cantini G, et al. Osteocalcin increase after bariatric surgery predicts androgen recovery in hypogonadal obese males. Int J Obes (Lond) 2014; 38:357-363.
6. Nimptsch K, Platz EA, Willett WC, Giovannucci E. Association between plasma 25-OH vitamin D and testosterone levels in men. Clin Endocrinol (Oxf) 2012; 77:106-112.
7. Lee DM, Tajar A, Pye SR, et al. Association of hypogonadism with vitamin D status: the European Male Ageing Study. EurJ Endocrinol 2012; 166:77-85.
8. Foresta C, Selice R, De Toni L, et al. Altered bone status in unilateral testicular cancer survivors: role of CYP2R1 and its luteinizing hormone-dependency. J Endocrinol Invest 2013; 36:379-384.
9. Duarte RV, Raphael JH, Southall JL, et al. Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy. BMJ Open 2013; 3:e002856.
10. Finch PM, Price LM, Pullan PT, Drummond PD. Effectsoftestosteronetreatment on bone mineral density in hypogonadal men receiving intrathecal opioids. Pain Pract 2014; Apr 1. doi: 10.1111/papr.12190. [Epub ahead of print]
11. Li L, Setoguchi S, Cabral H, Jick S. Opioid use for noncancer pain and risk of fracture in adults: a nested case-control study using the general practice research database. Am J Epidemiol 2013; 178:559-569.
12. Casado JL, Bañon S, Andrés R, et al. Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients. Osteoporos Int 2014; 25:1071-1079.
13. Wong P, Fuller PJ, Gillespie MT, et al. The effect of gonadal status on body composition and bone mineral density in transfusion-dependent thalassemia. Osteoporos Int 2014; 25:597-604.
14. Bouloux PM, Legros JJ, Elbers JM, et al., Study 43203 Investigators. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male 2013; 16:38-47.
15. Wang YJ, Zhan JK, Huang W, et al. Effects of low-dose testosterone undecanoate treatment on bone mineral density and bone turnover markers in elderly male osteoporosis with low serum testosterone. Int J Endocrinol 2013; Epub 2013 Mar 4. PMID:23533404 570413. doi: 10.1155/2013/570413.
16. Rodriguez-Tolrà J, Torremadé J, di Gregorio S, et al. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome. Andrology 2013; 1:570-575.
17. Borst SE, Yarrow JF, Conover CF, et al. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab 2014; 306:E433-442.
18. Haider A, Meergans U, Traish A, et al. Progressive improvement of t-scores in men with osteoporosis and subnormal serum testosterone levels upon treatment with testosterone over six years. Int J Endocrinol 2014; 496948. doi: 10.1155/2014/496948. Epub 2014 Feb 13.
19. Kacker R, Conners W, Zade J, Morgentaler A. Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility. J Urol 2014; 191:1072-1076.
20. Al Mukaddam M, Rajapakse CS, Bhagat YA, et al. Effects of testosterone and growth hormone on the structural and mechanical properties of bone by micro-MRI in the distal tibia of men with hypopituitarism. J Clin Endocrinol Metab 2014; 99:1236-1244.
21. Lee MJ, Ryu HK, An SY, et al. Testosterone replacement and bone mineral density in male pituitary tumor patients. Endocrinol Metab 2014; 29:48-53.
22. Tirabassi G, Delli Muti N, Gioia A, et al. Effects of testosterone replacement therapy on bone metabolism in male postsurgical hypogonadotropic hypo-gonadism: focus on the role of androgen receptor CAG polymorphism. J Endocrinol Invest 2014; 37:393-400.
23. Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; 367:1714-1723.